LL-37
LL-37 is a 37-amino-acid human cathelicidin peptide involved in innate immune defense and inflammatory signaling.
The short version
- Why people discuss it
- Discussed for antimicrobial, immune and skin/wound-related goals; its effects are not uniformly anti-inflammatory. Community interest does not establish benefit or a suitable treatment.
- What it is
- LL-37 is a 37-amino-acid human cathelicidin peptide involved in innate immune defense and inflammatory signaling.
- Biggest caution
- An endogenous defense role does not establish that systemic synthetic LL-37 is beneficial or safe. Its inflammatory and antimicrobial effects depend on concentration, tissue and experimental setting.
- Stack context
- Related profiles reflect adjacent community topics or biological context. They do not establish combination benefit, compatibility or a validated regimen.
Dose and frequency reference
Reference only — not a recommendation. Amounts describe source-specific community examples, selected study regimens or the named product label. They do not establish safety, effectiveness, product identity, or a suitable dose for any person. Never convert mg, mcg, or IU into syringe “units” without the exact product concentration.
Sources report different amounts or schedules; the reference below is a named example, not a consensus.
Subcutaneous injection
Community reference · Not clinical guidance- Amount
- 100–200 mcg
- Frequency
- Once daily
- Duration / phase
- 2–4 weeks
Community pattern; human studies used topical formulations Reference only; this does not establish safety, effectiveness or individual suitability.
Reference source · reviewed 2026-09-12Compare reported schedules
Saved source material reviewed 2026-09-27. Multiple pages from one publisher count as one source family; agreement does not establish what most people use. SC means subcutaneous; IM intramuscular; IP intraperitoneal.
- PeptideDosages — saved source reviewed September 27, 2026
50→400 mcg SC daily, 8–12 weeks, optional 16; cited human intervention studies are topical.
Evidence & sources · Community source profile
AxonRep synthesizes community discussion signals from its internal research corpus. Individual creator sources remain attributed to the synthesis; public reference sites used in the latest comparison are linked separately. The synthesis is not clinical evidence.
- AxonRep community research synthesisAxonRep synthesis · Checked 2026-09-12
- PeptideDosages — saved source reviewed September 27, 2026Community reference · Checked 2026-09-27